Tagged with P

Switzerland Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and haematology/oncology. Meyer discusses Blueprint’s innovative approach to international expansion, patient-centric strategy, and ambitious plans for growth in new markets. He…

Puerto Rico Yandia Perez is the executive vice president of the Puerto Rico Manufacturers Association (PRMA), an organization celebrating its 95th anniversary and dedicated to fostering a strong manufacturing ecosystem on the island. Under her leadership, PRMA has prioritized not only the pharmaceutical sector, which constitutes about 30% of Puerto Rico’s GDP,…

Global Traditional drug discovery is fraught with failure and often like trying to find a needle in a haystack. Even once a candidate is identified, the development process takes thousands of man-hours and generally billions of dollars. Artificial Intelligence has the potential to change this paradigm. It can aggregate and synthesize…

Global Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated by a mood of excitement, with Leqembi (lecanemab) – the second drug that targets Alzheimer’s disease progression by reducing amyloid…

USA The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win by Republican Donald Trump. “When it comes to elections we work with governments of all stripes everywhere,” Walmsley assured. With…

Japan At this year’s FT Live Global Pharma and Biotech Summit, Takeda’s President and CEO Christophe Weber spoke about the increased challenges for healthcare systems. Weber acknowledged that as cost pressures increase, innovators like Takeda will need to make difficult choices to optimize their investments. He also identified the Japanese pharma’s…

Switzerland Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines the importance of Switzerland as one of the French company’s key markets, the challenges and opportunities presented by the Swiss…

Switzerland Founded in 2020 with a focus on diseases related to skeletal muscle damage, MUVON Therapeutics is currently targeting a significant unmet need in women’s health, Female Stress Urinary Incontinence (SUI). CEO & co-founder Deana Mohr-Haralampieva, outlines MUVON’s progress into phase II clinical trials and its plans to raise EUR 65…

Switzerland Lars Nieba PhD, CEO of Engimmune, shares insights into the company’s innovative approach to T-cell therapies and its strategic direction as it prepares for its Series A funding round. Nieba discusses the promising therapeutic areas Engimmune is targeting—particularly liver cancer and immunology—and the company’s unique technology that harnesses soluble T-cell…

Switzerland Myriam DeLeone, General Manager of Amgen Switzerland, discusses the company’s commitment to tackling diseases prevalent in Switzerland such cardiovascular diseases and osteoporosis, Amgen’s expanding biosimilars profile, and how the company is leveraging Artificial Intelligence (AI), particularly to optimize drug development. DeLeone also comments on Switzerland’s concerning deficiencies in digitalization and access,…

UK A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern Ireland’s potential post-Brexit drug shortages, and Oxford Biomedica’s reband as OXB.   UK to create world-first ‘early warning system’ for…

Puerto Rico The Puerto Rico Consortium for Clinical Investigation (PRCCI) is a non-profit organisation offering specialised clinical trials services. Executive director Dr Amarilys Silva-Boschetti shares key developments since she last spoke with PharmaBoardroom in 2020, including the creation of a new clinical research centre with trials set to begin in 2024 and…